Intestinal bacteria and fatty liver disease study
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and the chemicals it makes are linked to a type of fatty liver disease called MAFLD. By joining, you'll help researchers understand this connection, which may lead to better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18 years old).
- You are either a healthy person with no liver disease, or you have been diagnosed with MAFLD (fatty liver disease linked to metabolism).
- If you have MAFLD, your diagnosis must be confirmed by imaging (like an ultrasound) or a liver biopsy showing fat in more than 5% of liver cells, and you must have at least one sign of metabolic syndrome (like high blood pressure, high blood sugar, or abnormal cholesterol).
- You have no other serious liver, stomach, kidney, or autoimmune diseases, and no history of cancer.
- You have not had an acute infection or inflammatory illness in the past month.
- You have not used laxatives, antibiotics, probiotics, prebiotics, proton pump inhibitors (like omeprazole), or other gut-affecting medications in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how common non-alcoholic fatty liver disease is in people with inflammatory bowel disease (Crohn's or colitis). Researchers want to learn more about the link between the two conditions.
This study looks at how your thyroid might be linked to fatty liver disease (MAFLD). It aims to help researchers understand if thyroid problems play a role in this condition, which could lead to better treatments.
This study looks at how gut bacteria change in people with liver cirrhosis and whether these changes relate to how the disease progresses. It may help find new ways to monitor or treat cirrhosis.
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.